Literature DB >> 22257753

Are females who inject drugs at higher risk for HIV infection than males who inject drugs: an international systematic review of high seroprevalence areas.

Don C Des Jarlais1, Jonathan P Feelemyer, Shilpa N Modi, Kamyar Arasteh, Holly Hagan.   

Abstract

OBJECTIVE: There are multiple reasons why females who inject drugs may be more likely to become infected with HIV than males who inject drugs. Where this is the case, special HIV prevention programs for females would be needed.
DESIGN: International systematic review and meta-analysis of studies across 14 countries.
METHODS: Countries with high seroprevalence (>20%) HIV epidemics among persons who inject drugs (PWID) were identified from the Reference Group to the UN on HIV and Injecting Drug Use. Systematic literature reviews collected data on HIV prevalence by gender for these countries. Non-parametric and parametric tests along with meta-analytic techniques examined heterogeneity and differences in odds ratios (OR) across studies.
RESULTS: Data were abstracted from 117 studies in 14 countries; total sample size N = 128,745. The mean weighted OR for HIV prevalence among females to males was 1.18 [95% CI 1.10-1.26], with high heterogeneity among studies (I(2)= 70.7%). There was a Gaussian distribution of the log ORs across studies in the sample.
CONCLUSION: There was a significantly higher HIV prevalence among females compared to males who inject drugs in high seroprevalence settings, but the effect size is extremely modest. The high level of heterogeneity and the Gaussian distribution suggest multiple causes of differences in HIV prevalence between females and males, with a specific difference determined by local factors. Greater understanding of factors that may protect females from HIV infection may provide insights into more effective HIV prevention for both females and males who inject drugs.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22257753      PMCID: PMC3353009          DOI: 10.1016/j.drugalcdep.2011.12.020

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  119 in total

1.  HIV seroprevalence in a facility for runaway and homeless adolescents.

Authors:  R L Stricof; J T Kennedy; T C Nattell; I B Weisfuse; L F Novick
Journal:  Am J Public Health       Date:  1991-05       Impact factor: 9.308

Review 2.  Review of sampling hard-to-reach and hidden populations for HIV surveillance.

Authors:  Robert Magnani; Keith Sabin; Tobi Saidel; Douglas Heckathorn
Journal:  AIDS       Date:  2005-05       Impact factor: 4.177

3.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987.

Authors:  D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky
Journal:  JAMA       Date:  1989-02-17       Impact factor: 56.272

4.  HIV and infections of similar transmission patterns in a drug injectors community of Santos, Brazil.

Authors:  H B de Carvalho; F Mesquita; E Massad; R C Bueno; G T Lopes; M A Ruiz; M N Burattini
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1996-05-01

5.  Death, AIDS morbidity, and HIV seroprevalence in New York City intravenous drug abusers.

Authors:  W Burkett; L S Brown
Journal:  J Natl Med Assoc       Date:  1990-11       Impact factor: 1.798

6.  [Prevalence of HIV infection among drug users in Zuid-Limburg].

Authors:  L G Wiessing; H Houweling; W A Meulders; E Cerdá; M Jansen; M J Sprenger
Journal:  Ned Tijdschr Geneeskd       Date:  1995-09-23

7.  Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: incidence, etiologies, and clinical aspects.

Authors:  A Boschini; C Smacchia; M Di Fine; A Schiesari; P Ballarini; M Arlotti; C Gabrielli; G Castellani; M Genova; P Pantani; A C Lepri; G Rezza
Journal:  Clin Infect Dis       Date:  1996-07       Impact factor: 9.079

8.  Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex- and age-specific survival of HIV-uninfected IDUs.

Authors:  Roberto Muga; Klaus Langohr; Jordi Tor; Arantza Sanvisens; Isabel Serra; Celestino Rey-Joly; Alvaro Muñoz
Journal:  Clin Infect Dis       Date:  2007-06-19       Impact factor: 9.079

9.  Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study.

Authors:  Jeppe B Schroll; Rasmus Moustgaard; Peter C Gøtzsche
Journal:  BMC Med Res Methodol       Date:  2011-02-24       Impact factor: 4.615

10.  Continued spread of HIV among injecting drug users in southern Sichuan Province, China.

Authors:  Lu Yin; Guangming Qin; Han-Zhu Qian; Yu Zhu; Wei Hu; Li Zhang; Kanglin Chen; Yunxia Wang; Shizhu Liu; Feng Zhou; Hui Xing; Yuhua Ruan; Ning Wang; Yiming Shao
Journal:  Harm Reduct J       Date:  2007-02-08
View more
  58 in total

1.  Gender, Transience, Network Partnerships and Risky Sexual Practices Among Young Persons who Inject Drugs.

Authors:  Anna L Hotton; Basmattee Boodram
Journal:  AIDS Behav       Date:  2017-04

2.  Female Gender and HIV Transmission Risk Behaviors Among People Living with HIV Who Have Ever Used Injection Drugs in St. Petersburg, Russia.

Authors:  Jennifer A Wagman; Jeffrey H Samet; Debbie M Cheng; Natalia Gnatienko; Anita Raj; Elena Blokhina; Olga Toussova; Leah S Forman; Dmitry Lioznov; Judith I Tsui
Journal:  AIDS Behav       Date:  2018-09

Review 3.  Drug use as a driver of HIV risks: re-emerging and emerging issues.

Authors:  Nabila El-Bassel; Stacey A Shaw; Anindita Dasgupta; Steffanie A Strathdee
Journal:  Curr Opin HIV AIDS       Date:  2014-03       Impact factor: 4.283

Review 4.  Biomedical HIV Prevention Including Pre-exposure Prophylaxis and Opiate Agonist Therapy for Women Who Inject Drugs: State of Research and Future Directions.

Authors:  Kimberly Page; Judith Tsui; Lisa Maher; Kachit Choopanya; Suphak Vanichseni; Philip A Mock; Connie Celum; Michael Martin
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

Review 5.  HIV Testing, Care, and Treatment Among Women Who Use Drugs From a Global Perspective: Progress and Challenges.

Authors:  Lisa Metsch; Morgan M Philbin; Carrigan Parish; Karen Shiu; Jemima A Frimpong; Le Minh Giang
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

6.  Drug Treatment as HIV Prevention Among Women and Girls Who Inject Drugs From a Global Perspective: Progress, Gaps, and Future Directions.

Authors:  Sandra A Springer; Sarah Larney; Zahra Alam-Mehrjerdi; Frederick L Altice; David Metzger; Steven Shoptaw
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

7.  Gender-Specific HIV Prevention Interventions for Women Who Use Alcohol and Other Drugs: The Evolution of the Science and Future Directions.

Authors:  Wendee M Wechsberg; Sherry Deren; Bronwyn Myers; Irma Kirtadze; William A Zule; Brittni Howard; Nabila El-Bassel
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

Review 8.  HIV, HCV, and Health-Related Harms Among Women Who Inject Drugs: Implications for Prevention and Treatment.

Authors:  Jenny Iversen; Kimberly Page; Annie Madden; Lisa Maher
Journal:  J Acquir Immune Defic Syndr       Date:  2015-06-01       Impact factor: 3.731

9.  Assessment of an electronic and clinician-delivered brief intervention on cigarette, alcohol and illicit drug use among women in a reproductive healthcare clinic.

Authors:  Ariadna Forray; Steve Martino; Kathryn Gilstad-Hayden; Trace Kershaw; Steve Ondersma; Todd Olmstead; Kimberly A Yonkers
Journal:  Addict Behav       Date:  2019-05-08       Impact factor: 3.913

Review 10.  ART uptake and adherence among women who use drugs globally: A scoping review.

Authors:  Jennifer L Glick; Aimee Huang; Rienna Russo; Belinda Jivapong; Vijayasundaram Ramasamy; Lori Rosman; Danielle Pelaez; Katherine H A Footer; Susan G Sherman
Journal:  Drug Alcohol Depend       Date:  2020-08-02       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.